8-modified-2′-deoxyadenosine analogues induce delayed polymerization arrest during hiv-1 reverse transcription

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Vivet Boudou, Valérie ^a   Isel, Catherine ^a   Sleiman, Marwan ^a   Smyth, Redmond ^b   Gaied, Nouha ^c   Barhoum, Patrick ^a   Laumond, Géraldine ^a   Bec, Guillaume ^a   Götte, Matthias ^d   Mak, Johnson ^b   Aubertin, Anne Marie ^a   Burger, Alain ^c   Marquet, Roland ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS   (France)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3',5' DI O ACETYL 8 CYANO 2' DEOXYADENOSINE; 3',5' DI O ACETYL 8 METHYLSULFONYL 2' DEOXYADENOSINE; 3',5' DI O ACETYL 8 METHYLTHIO 2' DEOXYADENOSINE; 5' O DIMETHOXYTRITYL 6 N DIMETHYLFORMAMIDINE NUCLEOSIDE DERIVATIVE; 5' O DIMETHOXYTRITYL 8 ETHYL 2' DEOXYADENOSINE; 6 N DIMETHYLFORMAMIDINE 5' O DIMETHOXYTRITYL 8 ETHYL 2' DEOXYADENOSINE; 6 N DIMETHYLFORMAMIDINE 5' O DIMETHOXYTRITYL 8 VINYL 2' DEOXYADENOSINE; 6 N DIMETHYLFORMAMIDINE NUCLEOSIDE DERIVATIVE; 8 AMINO 2' DEOXYADENOSINE DERIVATIVE; 8 CARBAMOYL 2' DEOXYADENOSINE; 8 ETHYL 2' DEOXYADENOSINE; 8 METHYLTHIO 2' DEOXYADENOSINE; 8 VINYL 2' DEOXYADENOSINE; DEOXYADENOSINE DERIVATIVE; UNCLASSIFIED DRUG; 2'-DEOXYADENOSINE; DEOXYADENOSINE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DNA STRAND; DNA SYNTHESIS INHIBITION; DNA TEMPLATE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; REVERSE TRANSCRIPTION; RNA TRANSLATION; VIRUS INHIBITION; VIRUS TRANSCRIPTION; CELL LINE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; DEOXYADENOSINES; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 80455158297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027456     Document Type: Article

References (41)

1. Skalka AM, Goff SP, (1993) Reverse Transcriptase. Cold Spring Harbor Monogr. Ser. Vol 23: 492.
2. Flexner C, (2007) HIV drug development: the next 25 years. Nat Rev 6: 959-966.
3. Pomerantz R, Horn DL, (2003) Twenty years of therapy for HIV-1 infection. Nat Med 9: 867-873.
4. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, et al. (2001) Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135: 17-26.
5. Greenberg M, Cammack N, Salgo M, Smiley L, (2004) HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 14: 321-337.
6. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
7. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287: 646-650.
8. Rittinger K, Divita G, Goody RS, (1995) Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors Proc Natl Acad Sci USA 92: 8046-8049.
9. Spence RA, Kati WM, Anderson KS, Johnson KA, (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267: 988-993.
10. Vivet-Boudou V, Didierjean J, Isel C, Marquet R, (2006) Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell Mol Life Sci 63: 163-186.
11. El Safadi Y, Vivet-Boudou V, Marquet R, (2007) HIV-1 reverse transcriptase inhibitors. Appl Microbiol Biotechnol 75: 723-737.
12. Sarafianos S, Marchand B, Das K, Himmel D, Parniak M, et al. (2009) Structure and function of HIV-1 reverse transcriptase: Molecular mechanisms of polymerization and inhibition. J Mol Biol 385: 693-713.
13. Preston BD, Poiesz BJ, Loeb LA, (1988) Fidelity of HIV-1 reverse transcriptase. Science 242: 1168-1171.
14. Roberts JD, Bebenek K, Kunkel TA, (1988) The accuracy of reverse transcriptase from HIV-1. Science 242: 1171-1173.
15. Menendez-Arias L, (2008) Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res 134: 124-146.
16. Acosta-Hoyos A, Scott W, (2010) The role of nucleotide excision by reverse transcriptase in HIV drug resistance. Viruses 2: 372-394.
17. Goldschmidt V, Marquet R, (2004) Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol 36: 1687-1705.
18. Boyer P, Julias JG, Marquez V, Hughes S, (2005) Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptase. J Mol Biol 345: 441-450.
19. Marquez VE, Hughes SH, Sei S, Agbaria R, (2006) The history of N-methanocarbathymidine: The investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent. Antiviral Res 71: 268-275.
20. Ohrui H, Mitsuya H, (2001) 4′-C-Substituted-2′-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants. Curr Drug Targets: Infectious Disorders 1: 1-10.
21. Kodama E, Kohgo S, Kitano K, Machida H, Gatanaga H, et al. (2001) 4-Ethynyl nucleoside analogs: potent inhibitors of multidrug resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 45: 1539-1546.
22. Kawamoto A, Kodama E, Sarafianos S, Sakagami Y, Kohgo S, et al. (2008) 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell B 40: 2410-2420.
23. Ohrui H, (2006) 2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Record 6: 133-143.
24. Michailidis E, Marchand B, Kodama E, Singh K, Matsuoka M, et al. (2009) Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem 284: 35681-35691.
25. Boyer P, Julias JG, Ambrose Z, Siddiqui M, Marquez V, et al. (2007) The nucleoside analogs 4′ C-methyl thymidine and 4′ C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants. J Mol Biol 371: 873-882.
26. Vu BC, Boyer PL, Siddiqui MA, Marquez VE, Hughes SH, (2011) 4′-C-Methyl-2′-deoxyadenosine and 4′-C-ethyl-2′-deoxyadenosine inhibit HIV-1 replication. Antimicrob Agents Chemother 55: 2379-2389.
27. Tchesnokov EP, Obikhod A, Schinazi RF, Gotte M, (2008) Delayed chain termination protects the anti-hepatitis B virus drug Entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem 283: 34218-34228.
28. Fukushima K, Ueno Y, Inoue J, Wakui Y, Obara N, et al. (2008) A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir. Hepatol Res 38: 842-846.
29. McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, et al. (2007) The HBV drug entecavir- effects on HIV-1 replication and resistance. N Engl J Med 356: 2614-2621.
30. Bebenek K, Beard WA, Darden TA, Li L, Prasad R, et al. (1997) A minor groove binding track in reverse transcriptase. Nat Struct Biol 4: 194-197.
31. Capek P, Pohl R, Hocek M, (2006) Cross-coupling reactions of unprotected halopurine bases, nucleosides, nucleotides and nucleoside triphosphates with 4-boronophenylalanine in water. Synthesis of (purin-8-yl)- and (purin-6-yl)phenylalanines. Org Biomol Chem 4: 2278-2284.
32. Long RA, Robins RK, Townsend LB, (1967) Purine nucleosides. XV. Synthesis of 8-amino- and 8-substituted aminopurine nucleosides. J Org Chem 32: 2751-2756.
33. Sagi G, Otvos L, Ikeda S, Andrei G, Snoeck R, et al. (1994) Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2′-deoxyadenosine analogs. J Med Chem 37: 1307-1311.
34. Huang H, Chopra R, Verdine GL, Harrison SC, (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282: 1669-1675.
35. Ben Gaied N, Glasser N, Ramalanjaona N, Beltz H, Wolff P, et al. (2005) 8-Vinyl-deoxyadenosine, an alternative fluorescent nucleoside analog to 2′-deoxyribosyl-2-aminopurine with improved properties. Nucleic Acids Res 33: 1031-1039.
36. Boyer PL, Vu BC, Ambrose Z, Julias JG, Warnecke S, et al. (2009) The nucleoside analogue D-carba T blocks HIV-1 reverse transcription. J Med Chem 52: 5356-5364.
37. El Safadi Y, Paillart J-C, Laumond G, Aubertin A-M, Burger A, et al. (2010) 5-Modified-2′-dU and 2′-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity. J Med Chem 53: 1534-1545.
38. Van Aerschot AA, Mamos P, Weyns NJ, Ikeda S, De Clercq E, et al. (1993) Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents. J Med Chem 36: 2938-2942.
39. Marquet R, Paillart J-C, Skripkin E, Ehresmann C, Ehresmann B, (1994) Dimerization of human immunodeficiency virus type 1 RNA involves sequences located upstream of the splice donor site. Nucleic Acids Res 22: 145-151.
40. Mizrahi V, Brooksbank RL, Nkabinde NC, (1994) Mutagenesis of the conserved aspartic acid 443, glutamic acid 478, asparagine 494, and aspartic acid 498 residues in the ribonuclease H domain of p66/p51 human immunodeficiency virus type I reverse transcriptase. Expression and biochemical analysis. J Biol Chem 269: 19245-19249.
41. Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, et al. (2002) Structural basis for inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 269: 1670-1677.